Solid Biosciences Inc. (SLDB) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
14/47
1.5 / 5 stars
All 47 Win/Lose results and 73 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 5 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinSLDB / S&P 38.75% / 15.20% |
No dataSLDB / S&P / 15.00% |
LoseSLDB / S&P -32.27% / 50.40% |
| 2026-Q11/2 |
WinSLDB / S&P 27.66% / -4.33% |
No dataSLDB / S&P / 11.30% |
LoseSLDB / S&P -35.22% / 27.70% |
| 2025-Q40/2 |
LoseSLDB / S&P -8.59% / 2.65% |
No dataSLDB / S&P / 9.00% |
LoseSLDB / S&P -33.99% / 13.40% |
| 2025-Q31/2 |
WinSLDB / S&P 26.69% / 8.12% |
No dataSLDB / S&P / 4.61% |
LoseSLDB / S&P -17.43% / 13.45% |
| 2025-Q21/2 |
WinSLDB / S&P 31.62% / 10.94% |
No dataSLDB / S&P / 4.83% |
LoseSLDB / S&P -14.55% / 10.63% |
| 2025-Q10/2 |
LoseSLDB / S&P -7.50% / -4.27% |
No dataSLDB / S&P / 4.98% |
LoseSLDB / S&P -23.60% / 10.57% |
| 2024-Q40/2 |
LoseSLDB / S&P -42.61% / 2.41% |
No dataSLDB / S&P / 5.25% |
LoseSLDB / S&P -36.78% / 6.15% |
| 2024-Q31/2 |
WinSLDB / S&P 22.93% / 5.89% |
No dataSLDB / S&P / 5.89% |
LoseSLDB / S&P -32.74% / 6.11% |
| 2024-Q20/2 |
LoseSLDB / S&P -57.43% / 4.28% |
No dataSLDB / S&P / 5.38% |
LoseSLDB / S&P -46.60% / 5.12% |
| 2024-Q11/2 |
WinSLDB / S&P 116.94% / 10.56% |
No dataSLDB / S&P / 5.71% |
LoseSLDB / S&P -52.30% / 5.59% |
| 2023-Q41/2 |
WinSLDB / S&P 143.65% / 11.69% |
No dataSLDB / S&P / 6.81% |
LoseSLDB / S&P -52.03% / 7.78% |
| 2023-Q30/2 |
LoseSLDB / S&P -51.91% / -3.27% |
No dataSLDB / S&P / 7.52% |
LoseSLDB / S&P -61.92% / -5.03% |
| 2023-Q21/2 |
WinSLDB / S&P 10.55% / 8.74% |
No dataSLDB / S&P / 9.50% |
LoseSLDB / S&P -46.54% / -8.57% |
| 2023-Q11/2 |
LoseSLDB / S&P -11.90% / 7.50% |
No dataSLDB / S&P / 10.77% |
WinSLDB / S&P -1.67% / -15.69% |
| 2022-Q40/1 |
LoseSLDB / S&P -23.20% / 7.56% |
No dataSLDB / S&P / 11.88% |
No dataSLDB / S&P / -17.99% |
| 2022-Q30/1 |
LoseSLDB / S&P -24.19% / -4.88% |
No dataSLDB / S&P / 13.47% |
No dataSLDB / S&P / -1.41% |
| 2022-Q20/1 |
LoseSLDB / S&P -48.67% / -16.10% |
No dataSLDB / S&P / 13.71% |
No dataSLDB / S&P / 11.04% |
| 2022-Q10/1 |
LoseSLDB / S&P -31.43% / -4.60% |
No dataSLDB / S&P / 15.97% |
No dataSLDB / S&P / 42.23% |
| 2021-Q40/1 |
LoseSLDB / S&P -26.78% / 11.03% |
No dataSLDB / S&P / 15.00% |
No dataSLDB / S&P / 96.40% |
| 2021-Q30/1 |
LoseSLDB / S&P -34.70% / 0.58% |
No dataSLDB / S&P / 10.77% |
No dataSLDB / S&P / 69.42% |
| 2021-Q20/1 |
LoseSLDB / S&P -33.82% / 8.55% |
No dataSLDB / S&P / 6.58% |
No dataSLDB / S&P / 51.81% |
| 2021-Q10/1 |
LoseSLDB / S&P -27.04% / 6.17% |
No dataSLDB / S&P / -1.06% |
No dataSLDB / S&P / 7.39% |
| 2020-Q41/1 |
WinSLDB / S&P 273.40% / 12.15% |
No dataSLDB / S&P / -3.72% |
No dataSLDB / S&P / -33.42% |
| 2020-Q30/1 |
LoseSLDB / S&P -30.72% / 8.93% |
No dataSLDB / S&P / -2.04% |
No dataSLDB / S&P / -27.10% |
| 2020-Q21/1 |
WinSLDB / S&P 22.59% / 20.54% |
No dataSLDB / S&P / -0.46% |
No dataSLDB / S&P / -27.11% |
| 2020-Q10/1 |
LoseSLDB / S&P -46.29% / -19.60% |
No dataSLDB / S&P / 3.47% |
No dataSLDB / S&P / -14.75% |
| 2019-Q40/1 |
LoseSLDB / S&P -56.96% / 9.07% |
No dataSLDB / S&P / 5.36% |
No dataSLDB / S&P / 2.99% |
| 2019-Q31/1 |
WinSLDB / S&P 79.83% / 1.70% |
No dataSLDB / S&P / 5.02% |
No dataSLDB / S&P / 0.21% |
| 2019-Q20/1 |
LoseSLDB / S&P -37.50% / 4.30% |
No dataSLDB / S&P / 6.64% |
No dataSLDB / S&P / 8.65% |
| 2019-Q10/1 |
LoseSLDB / S&P -65.67% / 13.65% |
No dataSLDB / S&P / 8.12% |
No dataSLDB / S&P / 14.29% |
| 2018-Q40/1 |
LoseSLDB / S&P -43.20% / -13.52% |
No dataSLDB / S&P / 9.05% |
No dataSLDB / S&P / 18.23% |
| 2018-Q31/1 |
WinSLDB / S&P 32.42% / 7.71% |
No dataSLDB / S&P / 10.21% |
No dataSLDB / S&P / 19.06% |
| 2018-Q21/1 |
WinSLDB / S&P 375.07% / 3.43% |
No dataSLDB / S&P / 9.03% |
No dataSLDB / S&P / 14.46% |
| 2018-Q10/0 |
No dataSLDB / S&P / -0.76% |
No dataSLDB / S&P / 7.68% |
No dataSLDB / S&P / 12.46% |
| 2017-Q40/0 |
No dataSLDB / S&P / 6.64% |
No dataSLDB / S&P / 7.03% |
No dataSLDB / S&P / 13.82% |
| 2017-Q30/0 |
No dataSLDB / S&P / 4.48% |
No dataSLDB / S&P / 5.68% |
No dataSLDB / S&P / 17.57% |
| 2017-Q20/0 |
No dataSLDB / S&P / 3.09% |
No dataSLDB / S&P / 4.83% |
No dataSLDB / S&P / 17.74% |
| 2017-Q10/0 |
No dataSLDB / S&P / 6.07% |
No dataSLDB / S&P / 3.67% |
No dataSLDB / S&P / 13.32% |
| 2016-Q40/0 |
No dataSLDB / S&P / 3.82% |
No dataSLDB / S&P / 2.09% |
No dataSLDB / S&P / 7.05% |
| 2016-Q30/0 |
No dataSLDB / S&P / 3.85% |
No dataSLDB / S&P / 0.20% |
No dataSLDB / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SLDB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 84.85% | 20.78% |
| Annualized return | 84.85% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SLDB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -75.44% | 83.14% |
| Annualized return | -24.48% | 12.86% |
10Y · 2018-01-26 to 2026-08-27
| Metric | SLDB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.01% | 319.30% |
| Annualized return | -29.61% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |